SJS/TEN 2021: Collaboration, Innovation and Community * is a two-day virtual meeting that builds on the success of the previous meetings SJS/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation and SJS/TEN 2019: From Science to Translation meetings held March 2, 2017 in Orlando and April 26 and 27, 2019 in Vancouver Canada respectively.
Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) is a life-threatening condition that is typically drug-induced and has a mortality rate of on average 20% but up to 50% or more in high-risk populations. In some cases the cause of SJS/TEN cannot be determined. For those that survive the acute phase, the recovery period is long, quality and productivity of life can be significantly affected and the medical community still struggles to understand the long-term effects of SJS/TEN. Although scientific advances are occurring rapidly, the optimal evidence-based acute and long-term management has yet to be determined. The concept of our meetings is a cross-disciplinary exchange that brings together the community of SJS/TEN Survivors, their families, Scientists and Clinicians to truly understand the impact of this disease and to continue to foster growth of a collaborative and interactive community and research network. As was achieved with SJS/TEN 2017 and SJS/TEN 2019 central to the meeting is the community engagement to identify unmet clinical, scientific and psychosocial needs. The meeting will aim to highlight cutting edge research that is relevant to core translational objectives of the prediction, prevention, earlier diagnosis and optimized treatment of SJS/TEN. A key aim integral to the SJSTEN meetings is to provide an integrative and multidisciplinary mentorship model and provide support and foster the careers of early investigators.
***Registration is complementary however to create a login to the webinar and access all conference materials you must register***
Key highlights of the SJSTEN 2021 meeting include:
*Funding for this conference was made possible by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) R13AR078623
Legal & Commerical Solicitation is Prohibited with Faculty & Conference Attendees
Privacy Policy | Terms & Conditions